HPS Pharmacies wish to advise that Link Healthcare have given notice of the discontinuation of:
Despite ongoing efforts, Link Healthcare have been unable to negotiate a sustainable supply from either the current or alternative manufacturers, and are now forced to discontinue this product, effective immediately.
Methysergide is the only ergot derivative indicated for the prevention of migraine on the Pharmaceutical Benefits Scheme.
The Therapeutic Guidelines: Neurology recommends beta-blockers, pizotifen, and verapamil as alternatives for migraine prophylaxis. The NPS article Headache – Diagnosing, managing and preventing, offers a brief overview and links to other resources.
Please retain this notice in a prominent position, including other related business units as a reminder for all staff members for one month.
Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please do not hesitate to contact your pharmacist at HPS Pharmacies or Link Healthcare Customer Service on 1800 181
Information regarding expected dates for supply may vary subject to delays which are out of our control. HPS Pharmacies does not accept responsibility for such changes but will endeavour to keep our clients updated as information is made available from drug manufacturers or wholesalers.